Related Experiment Video
Updated: Mar 19, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
[Diagnostic Values of IL-12 and IFN-γ for the Patients with Acute Leukemia]
Xiao-Cheng Wang1, Ze-Jun Yan1, Jing-Hua Wang1
1Department of Clinical Laboratorial Examination, Chengde Municipal Central Hospital, Chengde 067000, Hebei Province, China.
Insights
Serum levels of interleukin-12 (IL-12) and interferon-gamma (IFN-γ) are lower in acute leukemia (AL) patients. Monitoring these cytokine changes aids in diagnosing and treating AL.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Acute leukemia (AL) is a significant hematologic malignancy.
- Interleukin-12 (IL-12) and interferon-gamma (IFN-γ) are key cytokines involved in immune responses.
- Understanding cytokine profiles in AL is crucial for diagnosis and treatment monitoring.
Purpose of the Study:
- To evaluate the diagnostic utility of serum IL-12 and IFN-γ levels in patients with acute leukemia.
- To compare cytokine levels between untreated AL patients, those in remission, and healthy controls.
- To assess the correlation between IL-12 and IFN-γ levels and clinical parameters in AL.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to quantify IL-12 and IFN-γ levels.
- A cohort of 76 AL patients and 40 healthy controls were analyzed.
- Statistical analysis was performed to compare cytokine levels across different groups.
Main Results:
- Significantly lower IL-12 and IFN-γ levels were observed in untreated AL patients compared to controls.
- Post-treatment levels in complete remission (CR) patients increased but remained lower than controls.
- Non-remission (NR) patients showed persistently low cytokine levels.
- Higher IL-12 and IFN-γ levels were noted in AL-CR patients compared to AL-NR patients.
Conclusions:
- Serum IL-12 and IFN-γ levels are decreased in acute leukemia patients.
- Changes in IL-12 and IFN-γ levels show potential as biomarkers for diagnosing and monitoring AL treatment response.
Objective:
To explore the diagnostic values of interleukin-12 (IL-12) and interferon-γ (IFN-γ) for the patients with acute leukemia (AL).
Methods:
A total of 76 cases of AL were enrolled in this study, and the 40 healthy persons were used as control group. The levels of IL-12 and IFN-γ were determined by enzyme linked immunosorbent assay (ELISA). The results were analyzed.
Results:
The levels of IL-12 and IFN-γ in the untreated AL group, ALL and ANLL groups were lower significantly than those in the control group (P<0.05), there was no significant difference between untreated AL and ANLL groups (P>0.05). The levels of IL-12 and IFN-γ in CR patients of AL group after treatment obviously higher than that of patients before treatment (P<0.05), but there was no significant difference as campared with that in control. The levels of IL-12 and IFN-γ in NR patients of AL group after treatment were obviously lower than that in control group (P<0.05), but there was no significant difference in comparision with patients before treatment (P>0.05). The levels of IL-12 and IFN-γ of AL-CR and AL-NR patients before treatment were not significant difference before treatment (P>0.05). The levels of IL-12 and IFN-γ of AL-CR patients obviously higher than that in AL-NR patients (P<0.05). According to immure classification, the levels of IL-12 and IFN-γ of patients in untreated group were not significant difference. In regard to the clinical risk degree, the level of IL-12 of patients in untreated group was not obvious difference (P>0.05), but the level of IFN-γ of patients in untreated group was obvious different (P<0.05). The level of IL-12 of patients in untreated group positively correlated with level of IFN-γ (r=0.735, P<0.05), but the level of IL-12 did not significantly correlated with the level of IFN-γ (r=0.292, P>0.05).
Conclusion:
The serum levels of both IL-12 and IFN-γ are lower, but the changes of both serum levels may be helpful to diagnose and treatment of AL patients.
More Related Videos
09:52A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014